Finding the right treatment for each man

Thanks to your support we’re able to fund a team based at the MRC Clinical Trials Unit at University College London to quickly identify which treatments work best for which men with cancer that has spread beyond the prostate.  

During a clinical trial, researchers collect a lot of data on individual men. Usually, they look at these data as a whole, to see if a new treatment works better than the current standard. For example, trials have shown that adding treatments such as docetaxel, abiraterone and enzalutamide to hormone therapy can help men with advanced prostate cancer live longer. However, it is also important to know if these sorts of treatment work for all of the different types of men included in the trials. This needs a lot of data, and an individual trial may not be big enough.

That's why we're funding a team led by Professor Jayne Tierney to find a smarter way to use valuable clinical data. Professor Tierney's team is collecting results and data on individual men from lots of clinical trials around the world. Having more data means they can work out more reliably which men benefit most and which men benefit least from treatments. For example, they can work out if men whose cancer has spread a little respond to treatments in the same way as men whose cancer has spread a lot. This should ensure that the right groups of men are prioritised to receive these treatments. 

The research will also help identify those men who don’t respond to current treatments. They can be offered other treatments that are more suited to them, and may help them avoid unnecessary – and potentially life changing – side effects.

Professor Tierney’s work will ensure better information for men with advanced prostate cancer, and enable medical teams to find the right treatment for each man.

John Swayne, 59, from Melton Mowbray, Leicester, was diagnosed with advanced prostate cancer in May 2019. He was treated with a course of docetaxel chemotherapy before switching to the hormone therapy bicalutamide, and now feels back to his normal self.

From research idea to access for all

Idea

Using men’s clinical data in a smarter way is a key part of our Research Strategy. We want to make rapid change for men, by finding new answers from existing data. Professor Jayne Tierney and her team do an in-depth analysis of results and data from multiple completed trials. This is called a meta-analysis, and helps identify which groups of men will benefit from treatments such as the chemotherapy docetaxel or the anti-androgen abiraterone.  

Lab research

To quickly identify which treatments work best, the team cooperates with teams running clinical trials across the world. This is a win-win, as individual large trials may show if a treatment works (or not), and the detailed, robust analysis by our funded researchers can pinpoint precisely which group of men this treatment is best for.

Clinical trials

Most recently, the team has used data from the STAMPEDE (from the UK), CHAARTED (from the USA) and GETUG (from Europe) trials which looked at the effects of docetaxel. This means that the team has so far analysed data from over 2,000 men across the world. The results of the analysis can be used by clinicians to treat smarter, not harder.

Approved for use

The evidence produced by this type of analysis is very powerful and robust. This is so impactful that analyses from this team have already changed UK and international guidelines on which men to treat with radiotherapy.

Access for all

As well as working closely with us to influence the Government's Major Conditions Strategy, the team is working closely with the clinical community to ensure these recommendations are taken on board by clinicians, not just in the UK but globally.

What's next?

We're supporting the next steps in Professor Tierney's work to evaluate new treatments and ensure they reach men as soon as possible.

We also fund a range of research into treating men in a more precise way, including projects looking to use existing and new treatments more accurately.